HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Cardiac Arrhythmia Case Could Stoke International CBD Safety Worries

Executive Summary

A patient admitted to a US emergency department after experiencing dizziness and fainting without warning is found to have been using a cocktail of herbal dietary supplements, including CBD and CBG. The case could fuel international worries about CBD's safety, for example in the EU, where novel food applications were recently put on hold by EFSA because of safety data gaps. 

You may also be interested in...



Hemp Roundtable Says Safety Study Data Should Convince Congress On Lawful CBD Use

Study of 1,061 subjects showed oral CBD has robust safety profile, addressing FDA’s safety concerns and providing evidence to convince agency to take action on CBD regulation, say trade groups.

UK CBD Industry Vexed As FSA Publishes Searchable Public List – A Year Late

The UK Food Standards Agency has published its much anticipated searchable, online CBD public list. But after a long wait, the list's publication has triggered a wave of anxiety and criticism from CBD firms and experts. 

GSK Signals CBD Interest With Agreement For Potential Australian Launch

GSK will evaluate the launch potential in Australia of a non-prescription CBD product currently being studied as a short-term treatment for sleep disturbances. The firm also has first refusal to negotiate the rights to market the product – developed by Cann Group – in other countries around the world.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152629

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel